PT - JOURNAL ARTICLE AU - Zwyer, Michaela AU - Rutaihwa, Liliana K. AU - Windels, Etthel AU - Hella, Jerry AU - Menardo, Fabrizio AU - Sasamalo, Mohamed AU - Borrell, Sonia AU - Reinhard, Miriam AU - Dötsch, Anna AU - Hiza, Hellen AU - Stritt, Christoph AU - Sikalengo, George AU - Fenner, Lukas AU - De Jong, Bouke C. AU - Kato-Maeda, Midori AU - Jugheli, Levan AU - Ernst, Joel D. AU - Niemann, Stefan AU - Jeljeli, Leila AU - Ballif, Marie AU - Egger, Matthias AU - Rakotosamimanana, Niaina AU - Yeboah-Manu, Dorothy AU - Asare, Prince AU - Malla, Bijaya AU - Dou, Horng Yunn AU - Zetola, Nicolas AU - Wilkinson, Robert J. AU - Cox, Helen AU - Carter, E Jane AU - Gnokoro, Joachim AU - Yotebieng, Marcel AU - Gotuzzo, Eduardo AU - Abimiku, Alash’le AU - Anchalee, Avihingsanon AU - Xu, Zhi Ming AU - Fellay, Jacques AU - Portevin, Damien AU - Reither, Klaus AU - Stadler, Tanja AU - Gagneux, Sebastien AU - Brites, Daniela TI - Back-to-Africa introductions of <em>Mycobacterium tuberculosis</em> as the main cause of tuberculosis in Dar es Salaam, Tanzania AID - 10.1101/2022.09.29.22280296 DP - 2022 Jan 01 TA - medRxiv PG - 2022.09.29.22280296 4099 - http://medrxiv.org/content/early/2022/09/30/2022.09.29.22280296.short 4100 - http://medrxiv.org/content/early/2022/09/30/2022.09.29.22280296.full AB - In settings with high tuberculosis (TB) endemicity, various genotypes of the Mycobacterium tuberculosis complex (MTBC) often differ in prevalence. However, the factors leading to these differences remain poorly understood. Here we studied the MTBC population in Dar es Salaam, Tanzania over a six-year period, using 1,082 unique patient-derived MTBC whole-genome sequences (WGS) and associated clinical data. We show that the TB epidemic in Dar es Salaam is dominated by multiple genotypes introduced to Tanzania from different parts of the world during the last 300 years. The most common MTBC genotypes deriving from these introductions exhibited differences in transmission rates and in the duration of the infectious period, but little differences in overall fitness, as measured by the effective reproductive number. Moreover, measures of disease severity and bacterial load indicated no differences in virulence between these genotypes during active TB. Instead, the combination of an early introduction and a high transmission rate accounted for the high prevalence of L3.1.1, the most dominant MTBC genotype in our setting. Yet, a longer co-existence with the host population did not always result in a higher transmission rate, suggesting that distinct life-history traits have evolved in the different MTBC genotypes. Taken together, our results point to bacterial factors as important determinants of the TB epidemic in Dar es Salaam.Author summary Tuberculosis (TB) is the deadliest human infectious disease caused by one single agent, Mycobacterium tuberculosis (Mtb). The origins of Mtb have been traced to East Africa millennia ago, where it likely became adapted to infect and transmit in humans. Here we show that in Dar es Salaam, Tanzania, an East African setting with a very high burden of TB, infections are caused by distinct Mtb genotypes introduced in recent evolutionary times from different parts of the world. These genotypes differed in traits important to Mtb transmission in the Dar es Salaam host population; while some Mtb genotypes transmitted more efficiently during a certain period of time, others elicited that patients would be infectious for longer periods. These traits evolved independently in the different Mtb genotypes and could not be explained by the time of co-existence between the host population and the pathogen. This suggests that bacterial factors are important determinants of the TB epidemic. More generally, we demonstrate that distinct pathogenic life history characteristics can co-exist in one host population.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Swiss National Science Foundation (https://www.snf.ch; Grant No: CRSII5_177163, 310030_188888) and the European Research Council (https://erc.europa.eu/; Grant No: 883582). RJW is supported by the Francis Crick Institute which receives funding from Wellcome (FC0010218), Cancer Research UK (FC0010218), and the Medical Research Council (FC0010218). He also receives support from Welcome (203135).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of Nordwest und Zentralschweiz gave ethical approval for this work Ethics committee of Ifakara Health Institute Institutional Review Board board gave ethical approval for this work. Ethics committee of the National Institute for Medical Research in Tanzania Medical Research Coordinating Committee gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors